This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Xofigo® (radium-223 dichloride) Resources

Xofigo Header Image
Xofigo Patient leaflet
Xofigo Treatment Checklist
Radium-223 dichloride consensus publication

Positioning Xofigo (radium-223 dichloride) in the mCRPC treatment pathway

Oncology Homepage
Welcome to the home of Bayer Oncology
PP-PF-ONC-GB-0398, February 2024
Xofigo®▼ (radium-223 dichloride)
In mCRPC
PP-XOF-GB-0637, March 2025
Xofigo®▼ (radium-223 dichloride) Guidelines
PP-XOF-GB-0636, March 2025

PP-XOF-GB-0580 | August 2024